• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Long-term COVID-19 vaccine- and Omicron infection-induced humoral and cell-mediated immunity

tetano

Editor, Senior Moderator
Front Immunol


. 2024 Nov 21:15:1494432.
doi: 10.3389/fimmu.2024.1494432. eCollection 2024. Long-term COVID-19 vaccine- and Omicron infection-induced humoral and cell-mediated immunity

Milja Belik[SUP] 1 [/SUP], Arttu Reinholm[SUP] 1 [/SUP], Pekka Kolehmainen[SUP] 1 [/SUP], Jemna Heroum[SUP] 1 [/SUP], Sari Maljanen[SUP] 1 [/SUP], Eda Altan[SUP] 1 [/SUP], Pamela Österlund[SUP] 2 [/SUP], Larissa Laine[SUP] 2 [/SUP], Olli Ritvos[SUP] 3 [/SUP], Arja Pasternack[SUP] 3 [/SUP], Rauno A Naves[SUP] 3 [/SUP], Alina Iakubovskaia[SUP] 3 [/SUP], Alex-Mikael Barkoff[SUP] 1 [/SUP], Qiushui He[SUP] 1 4 [/SUP], Johanna Lempainen[SUP] 5 [/SUP], Paula A Tähtinen[SUP] 5 [/SUP], Lauri Ivaska[SUP] 4 5 [/SUP], Pinja Jalkanen[SUP] #[/SUP][SUP] 1 [/SUP], Ilkka Julkunen[SUP] #[/SUP][SUP] 1 4 6 [/SUP], Laura Kakkola[SUP] #[/SUP][SUP] 1 6 [/SUP]



Affiliations
Abstract

Introduction: Mutations occurring in the spike (S) protein of SARS-CoV-2 enables the virus to evade COVID-19 vaccine- and infection-induced immunity.
Methods: Here we provide a comprehensive analysis of humoral and cell-mediated immunity in 111 healthcare workers who received three or four vaccine doses and were followed up to 12 and 6 months, respectively, after the last vaccine dose. Omicron breakthrough infection occurred in 71% of the vaccinees, enabling evaluation of vaccine- and vaccine/infection-induced hybrid immunity.
Results: Neutralizing antibodies were the highest against the ancestral D614G and were sequentially reduced against the Omicron variants BA.2, BA.5 and XBB.1.5. S1-specific IgG and neutralizing antibody levels were significantly higher in infected than in uninfected vaccinees, and the fourth vaccine dose in combination with a breakthrough infection resulted in high neutralizing antibody levels against all variants. T cell-mediated immunity, instead, was well retained already after two vaccine doses, and was not significantly strengthened by additional booster vaccine doses or Omicron breakthrough infections.
Discussion: While humoral immunity is sensitive to mutations in the S protein and thus declined rapidly, the cell-mediated immunity is durable to antigenic variation, which may explain the good efficacy of COVID-19 vaccines against a severe disease.

Keywords: B cell responses; COVID-19; T cell responses; booster vaccination; cell-mediated immunity; hybrid immunity; long term immunity; mRNA vaccination.

 
Back
Top Bottom